PDS Biotechnology Pub. Oncology Development Overview and Risks
PDS Biotechnology Corp. released an overview of its oncology drug development programs, PDS0301 (formerly PDS01ADC and NHS-IL12) and PDS0101 (Versamune HPV). The filing details forward-looking statements regarding risks to these operations including reliance on additional financing, threats to intellectual property, and uncertainties in clinical trial results.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed